What Happened: SACHS's recent move, as outlined in a Form 4 filing with the U.S. Securities and Exchange Commission on Thursday, involves purchasing 5,000 shares of Vertex Pharmaceuticals. The total ...

Pharma Vertex, CRISPR's gene-editing therapy Casgevy wins early FDA nod to treat beta thalassemia By Kevin Dunleavy Jan 16, 2024 3:40pm CRISPR Vertex Pharmaceuticals FDA Casgevy (exa-cel) ...

In sickle cell disease, Vertex set a $2.2 million wholesale price for Casgevy. In an email, the company said the price is the same for beta thalassemia.

The $2.2 million therapy has come a long way since its groundbreaking sickle cell disease FDA approval in December and subsequent January nod in beta thalassemia. As Vertex looks to tap into the ...

Vertex Pharmaceuticals Incorporated Investors: [email protected] Media: [email protected] or International: +44 20 3204 5275 or U.S.: 617-341-6992 or Heather Nichols: +1 617-839-3607 ...

Vertex Announces Approval of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™, for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT) in Kingdom of Saudi ...

Vertex Pharmaceuticals Incorporated VRTX stock has declined 8.9% in the past three months. The deterioration was due to soft first-quarter results, slower-than-expected uptake of its newer drugs ...